Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

Correction

The original article [1] contains two errors in Table 2:

• 1) The data values in the rows ‘Disease control rate’ and ‘Objective response rate’ and the columns ‘With adverse events’ and ‘Without adverse events’ have mistakenly been interchanged between columns; the values ‘39 (32.77)’ and ‘6 (5.04)’ should be swapped with the values ‘82 (54.67)’ and ‘11 (7.33)’ respectively.

• 2) The value for the row ‘Median progression-free survival (IQR)’ for the ‘HR/OR’ sub-column should be 0.69, not 0.79.

Table 2 Correlation between presence of at least one anti-angiogenesis-related adverse event and antitumor efficacy of apatinib

As such, the table displayed ahead shows the correct presentation of Table 2 and should be considered instead.